|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-9-27
|
|
pubmed:abstractText |
Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(?) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1477-2566
|
|
pubmed:author |
pubmed-author:AndersenMads HMH,
pubmed-author:BerntsenAnnikaA,
pubmed-author:BjørnJonJ,
pubmed-author:GeertsenPoul FPF,
pubmed-author:HadrupSine RekerSR,
pubmed-author:JohansenJulia SJS,
pubmed-author:LorentzenTorbenT,
pubmed-author:PedersenAnders EAE,
pubmed-author:SoleimaniAmirA,
pubmed-author:StratenPer ThorPT,
pubmed-author:SvaneInge MarieIM,
pubmed-author:TrepiakasRedasR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
721-34
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20429791-Adult,
pubmed-meshheading:20429791-Aged,
pubmed-meshheading:20429791-Aged, 80 and over,
pubmed-meshheading:20429791-Antigens, Neoplasm,
pubmed-meshheading:20429791-Cancer Vaccines,
pubmed-meshheading:20429791-Cells, Cultured,
pubmed-meshheading:20429791-Dendritic Cells,
pubmed-meshheading:20429791-Female,
pubmed-meshheading:20429791-Follow-Up Studies,
pubmed-meshheading:20429791-HLA-A2 Antigen,
pubmed-meshheading:20429791-Humans,
pubmed-meshheading:20429791-Interferon-alpha,
pubmed-meshheading:20429791-Interleukin-2,
pubmed-meshheading:20429791-Lymphocyte Activation,
pubmed-meshheading:20429791-Male,
pubmed-meshheading:20429791-Melanoma,
pubmed-meshheading:20429791-Middle Aged,
pubmed-meshheading:20429791-Skin Neoplasms,
pubmed-meshheading:20429791-Survival Analysis,
pubmed-meshheading:20429791-T-Lymphocytes
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
|
|
pubmed:affiliation |
Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev Hospital, Herlev, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
